618092-40-3

Basic information

• Product Name: 1-(2-FLUOROPHENYL)-5-METHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID
• Synonyms: SALOR-INT L317713-1EA;1-(2-FLUOROPHENYL)-5-METHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID;AKOS BBV-013015;OTAVA-BB 1218828
• CAS NO: 618092-40-3
• Molecular Formula: C11H9FN2O2
• Molecular Weight: 220.2
• Mol File: 618092-40-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(2-FLUOROPHENYL)-5-METHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-FLUOROPHENYL)-5-METHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID(618092-40-3)
• EPA Substance Registry System: 1-(2-FLUOROPHENYL)-5-METHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID(618092-40-3)

Safety Data

• Hazardous Substances Data: 618092-40-3(Hazardous Substances Data)

Usage

Chemical class

Pyrazole derivative

Functional groups

Carboxylic acid, fluorophenyl, and methyl substituent

Potential applications

Pharmaceutical and agrochemical industries

Specific use

Development of new drugs and pesticides

Structural characteristics

Unique arrangement of functional groups and substituents

Research and development

Suitable for further studies in the fields of pharmaceuticals and agrochemicals

Synthesis and characterization

Provides insights into the chemical properties and reactivity of pyrazole derivatives

Contribution to knowledge

Expands the understanding of organic chemistry

Upstream product

• 618092-38-9 C₁₃H₁₃FN₂O₂ 

Relevant articles and documents

Pyrazole-4-Carboxamide (YW2065): A Therapeutic Candidate for Colorectal Cancer via Dual Activities of Wnt/β-Catenin Signaling Inhibition and AMP-Activated Protein Kinase (AMPK) Activation

Dysregulation of the Wnt/β-catenin signaling pathway has been widely recognized as a pathogenic mechanism for colorectal cancer (CRC). Although numerous Wnt inhibitors have been developed, they commonly suffer from toxicity and unintended effects. Moreover, concerns have been raised in targeting this pathway because of its critical roles in maintaining stem cells and regenerating tissues and organs. On the basis of the anthelmintic drug pyrvinium and previous lead FX1128, we have developed a compound YW2065 (1c) which demonstrated excellent anti-CRC effects in vitro and in vivo. YW2065 achieves its inhibitory activity for Wnt signaling by stabilizing Axin-1, a scaffolding protein that regulates proteasome degradation of β-catenin. Simultaneously, YW2065 also led to the activation of the tumor suppressor AMPK, providing an additional anticancer mechanism. In addition, YW2065 showed favorable pharmacokinetic properties without obvious toxicity. The anti-CRC effect of YW2065 was highlighted by its promising efficacy in a mice xenograft model.

WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE

Compounds and compositions are provided as inhibitors of the Wnt/β-catenin pathway for the treatment of diseases that implicate the same.